{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T20:57:21Z","timestamp":1709931441342},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,6,20]],"date-time":"2015-06-20T00:00:00Z","timestamp":1434758400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s00108-015-3703-2","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T09:34:50Z","timestamp":1434620090000},"page":"791-802","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chronische Herzinsuffizienz"],"prefix":"10.1007","volume":"56","author":[{"given":"S.","family":"Ewen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,20]]},"reference":[{"key":"3703_CR1","first-page":"1787","volume":"J","author":"McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD et\u00a0al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart\u00a0J 33:1787\u20131847","journal-title":"Eur Heart"},{"key":"3703_CR2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jchf.2013.07.009","volume":"2","author":"Thibodeau","year":"2014","unstructured":"Thibodeau JT, Turer AT, Gualano SK et\u00a0al (2014) Characterization of a novel symptom of advanced heart failure: bendopnea. JACC Heart Fail 2:24\u201331","journal-title":"JACC Heart Fail"},{"key":"3703_CR3","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","volume":"376","author":"B\u00f6hm","year":"2010","unstructured":"B\u00f6hm M, Swedberg K, Komajda M et\u00a0al (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376:886\u2013894","journal-title":"Lancet"},{"key":"3703_CR4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00392-012-0467-8","volume":"102","author":"B\u00f6hm","year":"2013","unstructured":"B\u00f6hm M, Borer J, Ford I et\u00a0al (2013) Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 102:11\u201322","journal-title":"Clin Res Cardiol"},{"key":"3703_CR5","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00392-013-0558-1","volume":"102","author":"Schuchert","year":"2013","unstructured":"Schuchert A, Muto C, Maounis T et\u00a0al (2013) One-year outcome after CRT implantation in NYHA class\u00a0IV in comparison to NYHA class\u00a0III patients. Clin Res Cardiol 102:505\u2013511","journal-title":"Clin Res Cardiol"},{"key":"3703_CR6","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","volume":"384","author":"Kotecha","year":"2014","unstructured":"Kotecha D, Holmes J, Krum H et\u00a0al (2014) Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 384:2235\u20132243","journal-title":"Lancet"},{"key":"3703_CR7","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","volume":"150","author":"McAlister","year":"2009","unstructured":"McAlister FA, Wiebe N, Ezekowitz JA et\u00a0al (2009) Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150:784\u2013794","journal-title":"Ann Intern Med"},{"key":"3703_CR8","doi-asserted-by":"crossref","unstructured":"Castagno D, Skali H, Takeuchi M et\u00a0al (2012) Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J\u00a0Am Coll Cardiol 59:1785\u20131795","DOI":"10.1016\/j.jacc.2011.12.044"},{"key":"3703_CR9","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ejhf.85","volume":"16","author":"B\u00f6hm","year":"2014","unstructured":"B\u00f6hm M, Perez AC, Jhund PS et\u00a0al (2014) Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). Eur J Heart Fail 16:778\u2013787","journal-title":"Eur J Heart Fail"},{"key":"3703_CR10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00392-010-0207-x","volume":"100","author":"Reil","year":"2011","unstructured":"Reil JC, Custodis F, Swedberg K et\u00a0al (2011) Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 100:11\u201319","journal-title":"Clin Res Cardiol"},{"key":"3703_CR11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00392-013-0644-4","volume":"103","author":"Lonn","year":"2014","unstructured":"Lonn EM, Rambihar S, Gao P et\u00a0al (2014) Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET\/TRANSCEND. Clin Res Cardiol 103:149\u2013159","journal-title":"Clin Res Cardiol"},{"key":"3703_CR12","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M et\u00a0al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875\u2013885","journal-title":"Lancet"},{"key":"3703_CR13","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/eurheartj\/ehu401","volume":"J","author":"Vazir","year":"2015","unstructured":"Vazir A, Claggett B, Jhund P et\u00a0al (2015) Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. Eur Heart\u00a0J 36:669\u2013675","journal-title":"Eur Heart"},{"key":"3703_CR14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00392-012-0489-2","volume":"102","author":"Franke","year":"2013","unstructured":"Franke J, Wolter JS, Meme L et\u00a0al (2013) Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed? Clin Res Cardiol 102:23\u201331","journal-title":"Clin Res Cardiol"},{"key":"3703_CR15","doi-asserted-by":"crossref","unstructured":"Zannad F, McMurray JJ, Krum H et\u00a0al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N\u00a0Engl J Med 364:11\u201321","DOI":"10.1056\/NEJMoa1009492"},{"key":"3703_CR16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/CIRCHEARTFAILURE.112.000173","volume":"6","author":"Krum","year":"2013","unstructured":"Krum H, Shi H, Pitt B et\u00a0al (2013) Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Circ Heart Fail 6:711\u2013718","journal-title":"Circ Heart Fail"},{"key":"3703_CR17","doi-asserted-by":"crossref","unstructured":"Pitt B, Zannad F, Remme WJ et\u00a0al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N\u00a0Engl J Med 341:709\u2013717","DOI":"10.1056\/NEJM199909023411001"},{"key":"3703_CR18","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.amjmed.2011.12.018","volume":"125","author":"Chatterjee","year":"2012","unstructured":"Chatterjee S, Moeller C, Shah N et\u00a0al (2012) Eplerenone is not superior to older and less expensive aldosterone antagonists. Am J Med 125:817\u2013825","journal-title":"Am J Med"},{"key":"3703_CR19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00392-014-0678-2","volume":"103","author":"Tebbe","year":"2014","unstructured":"Tebbe U, Tschope C, Wirtz JH et\u00a0al (2014) Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clin Res Cardiol 103:665\u2013673","journal-title":"Clin Res Cardiol"},{"key":"3703_CR20","doi-asserted-by":"crossref","unstructured":"Pitt B, Pfeffer MA, Assmann SF et\u00a0al (2014) Spironolactone for heart failure with preserved ejection fraction. N\u00a0Engl J Med 370:1383\u20131392","DOI":"10.1056\/NEJMoa1313731"},{"key":"3703_CR21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF et\u00a0al (2015) Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131:34\u201342","journal-title":"Circulation"},{"key":"3703_CR22","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.ahj.2009.12.044","volume":"J","author":"Simes","year":"2010","unstructured":"Simes RJ, O\u2019Connell RL, Aylward PE et\u00a0al (2010) Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. Am Heart\u00a0J 159:988\u2013997","journal-title":"Am Heart"},{"key":"3703_CR23","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.hfc.2011.06.004","volume":"7","author":"Fiuzat","year":"2011","unstructured":"Fiuzat M, Califf RM (2011) Conduct of clinical trials in acute heart failure: regional differences in heart failure clinical trials. Heart Fail Clin 7:539\u2013544","journal-title":"Heart Fail Clin"},{"key":"3703_CR24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00392-012-0531-4","volume":"102","author":"Schowalter","year":"2013","unstructured":"Schowalter M, Gelbrich G, Stork S et\u00a0al (2013) Generic and disease-specific health-related quality of life in patients with chronic systolic heart failure: impact of depression. Clin Res Cardiol 102:269\u2013278","journal-title":"Clin Res Cardiol"},{"key":"3703_CR25","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/1745-6215-12-194","volume":"12","author":"Savard","year":"2011","unstructured":"Savard LA, Thompson DR, Clark AM (2011) A meta-review of evidence on heart failure disease management programs: the challenges of describing and synthesizing evidence on complex interventions. Trials 12:194","journal-title":"Trials"},{"key":"3703_CR26","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/eurjhf\/hfq192","volume":"12","author":"Dickstein","year":"2010","unstructured":"Dickstein K, Vardas PE, Auricchio A et\u00a0al (2010) 2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail 12:1143\u20131153","journal-title":"Eur J Heart Fail"},{"key":"3703_CR27","doi-asserted-by":"crossref","unstructured":"Tang AS, Wells GA, Talajic M et\u00a0al (2010) Cardiac-resynchronization therapy for mild-to-moderate heart failure. N\u00a0Engl J Med 363:2385\u20132395","DOI":"10.1056\/NEJMoa1009540"},{"key":"3703_CR28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/CIRCHEARTFAILURE.112.968867","volume":"5","author":"Healey","year":"2012","unstructured":"Healey JS, Hohnloser SH, Exner DV et\u00a0al (2012) Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail 5:566\u2013570","journal-title":"Circ Heart Fail"},{"key":"3703_CR29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/eurheartj\/16.suppl_F.4","volume":"J","author":"Packer","year":"1995","unstructured":"Packer M (1995) Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. Eur Heart\u00a0J 16(Suppl\u00a0F):4\u20136","journal-title":"Eur Heart"},{"key":"3703_CR30","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","volume":"375","author":"Ruilope","year":"2010","unstructured":"Ruilope LM, Dukat A, B\u00f6hm M et\u00a0al (2010) Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin\u00a0II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375:1255\u20131266","journal-title":"Lancet"},{"key":"3703_CR31","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","volume":"380","author":"Solomon","year":"2012","unstructured":"Solomon SD, Zile M, Pieske B et\u00a0al (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase\u00a02 double-blind randomised controlled trial. Lancet 380:1387\u20131395","journal-title":"Lancet"},{"key":"3703_CR32","doi-asserted-by":"crossref","unstructured":"McMurray JJ, Packer M, Desai AS et\u00a0al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N\u00a0Engl J Med 371:993\u20131004","DOI":"10.1056\/NEJMoa1409077"},{"key":"3703_CR33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","volume":"131","author":"Packer","year":"2015","unstructured":"Packer M, McMurray JJ, Desai AS et\u00a0al (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131:54\u201361","journal-title":"Circulation"},{"key":"3703_CR34","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00392-014-0726-y","volume":"103","author":"Sabouret","year":"2014","unstructured":"Sabouret P, Depret-Bixio L, Cotte FE et\u00a0al (2014) Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) database. Clin Res Cardiol 103:887\u2013893","journal-title":"Clin Res Cardiol"},{"key":"3703_CR35","doi-asserted-by":"crossref","unstructured":"Pozzoli M, Cioffi G, Traversi E et\u00a0al (1998) Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344\u00a0patients with baseline sinus rhythm. J\u00a0Am Coll Cardiol 32:197\u2013204","DOI":"10.1016\/S0735-1097(98)00221-6"},{"key":"3703_CR36","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.111.962688","volume":"4","author":"Chamberlain","year":"2011","unstructured":"Chamberlain AM, Redfield MM, Alonso A et\u00a0al (2011) Atrial fibrillation and mortality in heart failure: a community study. Circ Heart Fail 4:740\u2013746","journal-title":"Circ Heart Fail"},{"key":"3703_CR37","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.amjmed.2014.06.006","volume":"127","author":"Aleong","year":"2014","unstructured":"Aleong RG, Sauer WH, Davis G et\u00a0al (2014) New-onset atrial fibrillation predicts heart failure progression. Am J Med 127:963\u2013971","journal-title":"Am J Med"},{"key":"3703_CR38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1161\/CIRCHEARTFAILURE.113.000568","volume":"7","author":"Zakeri","year":"2014","unstructured":"Zakeri R, Borlaug BA, McNulty SE et\u00a0al (2014) Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ Heart Fail 7:123\u2013130","journal-title":"Circ Heart Fail"},{"key":"3703_CR39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"Rossignol","year":"2014","unstructured":"Rossignol P, Dobre D, McMurray JJ et\u00a0al (2014) Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 7:51\u201358","journal-title":"Circ Heart Fail"},{"key":"3703_CR40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","volume":"125","author":"Rossignol","year":"2012","unstructured":"Rossignol P, Cleland JG, Bhandari S et\u00a0al (2012) Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation 125:271\u2013279","journal-title":"Circulation"},{"key":"3703_CR41","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","volume":"7","author":"Vardeny","year":"2014","unstructured":"Vardeny O, Claggett B, Anand I et\u00a0al (2014) Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 7:573\u2013579","journal-title":"Circ Heart Fail"},{"key":"3703_CR42","doi-asserted-by":"crossref","unstructured":"Packham DK, Rasmussen HS, Lavin PT et\u00a0al (2015) Sodium zirconium cyclosilicate in hyperkalemia. N\u00a0Engl J Med 372:222\u2013231","DOI":"10.1056\/NEJMoa1411487"},{"key":"3703_CR43","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","volume":"312","author":"Kosiborod","year":"2014","unstructured":"Kosiborod M, Rasmussen HS, Lavin P et\u00a0al (2014) Effect of sodium zirconium cyclosilicate on potassium lowering for 28\u00a0days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 312:2223\u20132233","journal-title":"JAMA"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-015-3703-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-015-3703-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-015-3703-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T04:17:42Z","timestamp":1558585062000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-015-3703-2"}},"subtitle":["Aktuelle Leitlinienempfehlungen und neue Erkenntnisse"],"short-title":[],"issued":{"date-parts":[[2015,6,20]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["3703"],"URL":"https:\/\/doi.org\/10.1007\/s00108-015-3703-2","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,20]]}}}